The prevalence of 4G5G polymorphism of plasminogen activator ihibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels

European Journal of Endocrinology

Volumn 150, Issue 6, 2004, Pages 793-798

  Diamanti Kandarakis, Evanthia ^a   Palioniko, Gaetano ^a   Alexandraki, Krystallenia ^a   Bergiele, Angeliki ^a   Koutsouba, Thenia ^a   Bartzis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TESTOSTERONE;

ADULT; ALLELE; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; BLOOD; BODY CONSTITUTION; GENE FREQUENCY; GENETICS; GLUCOSE BLOOD LEVEL;

ADULT; ALLELES; BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TESTOSTERONE;

EID: 3242720491     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500793     Document Type: Article

References (23)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR & Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998 83 3078-3082.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999 84 4006-4011.
3. Diamanti-Kandarakis E & Dunaif A. New perspectives in polycystic ovary syndrome. Trends in Endocrinology and Metabolism 1996 7 267-271.
4. Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G & Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertility and Sterility 1994 61 455-460.
5. Diamanti-Kandarakis E, Spina G, Kouli C & Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. Journal of Clinical Endocrinology and Metabolism 2001 86 4666-4673.
6. Diamanti-Kandarakis E, Paterakis T, Rizos D, Chatzismalis P, Alexandraki K, Nikolopoulou M et al. Adhesion molecules in PCOS. The impact of the human genome on endocrinology. Program and abstracts, The Endocrine Society's 84th Annual Meeting, San Francisco, CA, USA. 2002 Abstract P2-615.
7. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P & Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. PNAS 1995 92 1851-1855.
8. Sampson M, Kong C, Patel A, Unwin R & Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology 1996 45 623-629.
9. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH & Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertility and Sterility 1998 69 236-241.
10. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thrombosis and Haemostasis 1998 79 975-979.
11. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW & Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thrombosis and Haemostasis 1999 82 1121-1126.
12. Grancha S, Estelles A, Torno G, Falco C, Gilabert J, Espana F et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thrombosis and Haemostasis 1999 81 516-521.
13. Follo M & Ginsburg D. Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1. Gene 1989 84 447-453.
14. Sprengers ED & Kluft C. Plasminogen activator inhibitors. Blood 1987 69 381-387.
15. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S & Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. Journal of Biological Chemistry 1993 268 10739-10745.
16. Siegel S, Castellan NJ. In Non Parametric Statistics for the Behavioural Sciences, edn 2, ch 6, pp 102-166. Eds S Siegel & NJ Castellan. McGraw-Hill: New York, 1988.
17. Tabachnik BG & Fidell LS. In Using Multivariate Statistics, edn 2, ch 9, pp 371-435. Eds Tabachnik BG & Fidell LS. New York: Harper & Row, 1989.
18. Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Resolution 1994 25 85-92.
19. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE & Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995 44 37-42.
20. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin levels and relative body weight in normal and obese subjects. Metabolism 1986 35 250-253.
21. Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice A et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clinical Endocrinology 2000 52 487-492.
22. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T & Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999 48 1589-1595.
23. Liu YX. Regulation of the plasminogen activator system in the ovary. Biological Signals and Receptors 1999 8 160-177.